ja_mageia

NEUROFIBROMATOSIS CLINICAL TRIAL AWARDS

In 2006, the Children's Tumor Foundation developed a Strategic Plan for accelerating neurofibromatosis (NF) research to the clinic. One of the priorities identified was the need to fund early-stage pilot clinical trials of candidate NF therapeutics. Implementing these strategic recommendations, the Foundation now announces the availability of NF Clinical Trial Awards.

Funding Available

NF Clinical Trial Awards of up to $125,000 total award are available to support pilot-scale clinical testing of potential candidate therapeutics for the treatment of tumors and other manifestations of NF1, NF2 or Schwannomatosis.

Application Process

Applicants must submit a Letter of Intent (LOI), by completing the LOI application form in this packet. We aim to have this reviewed in 4-6 weeks. If this is approved you will be invited to submit a full application.

Once your LOI approved, the full application may be submitted at any time.

DOWNLOAD THE LOI APPLICATION PACKET

Before submitting your LOI, you are strongly encouraged to contact me to discuss your idea.

Good Luck!

Kim Hunter-Schaedle, Ph.D.
Chief Scientific Officer
Children's Tumor Foundation
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel: 212-344-6633 x231

Currently Funded Clinical Trial Awards 2009

Phase 0 Trial of Tykerb (Lapatinib) for NF2 Vestibular Schwannoma
Principal Investigators: Dr. Jaishri Blakeley (Johns Hopkins University) and Dr. Matthias Karajannis (New York University Langone Medical Center)
Collaborating Sites: Ohio State University, and the House Ear Institute. GlaxoSmithKline is providing the drug as well as technical support for the study.  

Phase I Trial of Nexavar (Sorafenib) for NF1 Plexiform Neurofibroma
Principal Investigators: Dr. Bruce Korf (University of Alabama at Birmingham), Dr. Aerang Kim and Dr. Brigitte Widemann at (NIH-NCI)  
Collaborating site: Children’s Hospital of Philadelphia